Glaxo SmithKline Taking Soft Merger Route: Will Start With Two U.S. Heads
Executive Summary
The U.S. pharmaceutical operations of Glaxo Wellcome and SmithKline Beecham will not be combined immediately as part of the merger integration process.
You may also be interested in...
Glaxo SmithKline
Merged company will not create new global headquarters in the New York/New Jersey region as previously announced (1"The Pink Sheet" Jan. 24, p. 18). U.S. operations will instead be based out of existing companies' headquarters in Research Triangle Park, N.C. (Glaxo Wellcome) and Philadelphia (SmithKline Beecham). Sales and marketing components in the U.S. will also remain separate during the first phases of the merger process (2"The Pink Sheet" Feb. 7, p. 19)
Glaxo SmithKline
Merged company will not create new global headquarters in the New York/New Jersey region as previously announced (1"The Pink Sheet" Jan. 24, p. 18). U.S. operations will instead be based out of existing companies' headquarters in Research Triangle Park, N.C. (Glaxo Wellcome) and Philadelphia (SmithKline Beecham). Sales and marketing components in the U.S. will also remain separate during the first phases of the merger process (2"The Pink Sheet" Feb. 7, p. 19)
Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics
Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.